

## AAVACC APPOINTS DR RANDOLPH SEIDLER AS A NON-EXECUTIVE DIRECTOR

**Singapore, 28**<sup>th</sup> **August 2019** – AAVACC announced today that Dr Randolph Seidler has been appointed to the company's Board as a Non-Executive Director.

Dr Seidler worked at Boehringer Ingelheim for over 20 years, where starting in 2006, he specialized in animal health. Since then he has led both Global R&D and Business Development at Boehringer Ingelheim Animal Health with a specific focus on innovation in vaccines and pharmaceuticals. He managed teams in North America, Europe and Asia and oversaw the licensing, development and regulatory approval of numerous successful vaccines in life stock and companion animals.

Dr Peter Moran, a COO of AAVACC, said: "Randolph is certainly one of the best known and respected people within the animal health field and we are extremely privileged and excited to have him on our Board. We have already been interacting intensively with him over an extended period and his insights are industry contacts invaluable."

Dr Seidler commented: "I have been following ACM Biolabs and AAVACC for a number of years and their proprietary polymersome technology holds great promise to successfully address various difficult disease targets as well as allow a step change in the way vaccines are manufactured, for example by reducing or eliminating biosafety concerns. I am very much looking forward to being part of the team that will bring this technology into full commercial production."

## **About AAVACC Pte Ltd**

AAVACC Pte Ltd is a subsidiary of ACM Biolabs Pte Ltd and is focused on the development and commercialization of ACM-based veterinary vaccines. ACM Biolabs is a synthetic biology company using its proprietary Artificial Cell Membrane ("ACM") technology platform to develop novel vaccines. AAVACC has licensed technology from ACM Biolabs, the Agency for Science, Technology and Research (A\*STAR), Singapore's lead public sector agency for science, research and development, and from Nanyang Technological University (NTU) a research-intensive University in Singapore which is consistently ranked among the world's best Universities.

Media Contact: <a href="mailto:info@AAVACC.com">info@AAVACC.com</a>

Website: <a href="www.AAVACC.com">www.AAVACC.com</a>
General Email: <a href="mailto:info@AAVACC.com">info@AAVACC.com</a>
© AAVACC 2019. Leaders in Synthetic Veterinary Vaccines Page 1 of 1